Table 1.
No. | Start | End | Peptide | Length |
---|---|---|---|---|
1 | 15 | 23 | GCMVQVTCG | 9 |
2 | 32 | 45 | LDDVVYCPRHVICT | 14 |
3 | 65 | 72 | NFLVQAGN | 8 |
4 | 83 | 91 | QNCVLKLKV | 9 |
5 | 101 | 107 | YKFVRIQ | 7 |
6 | 111 | 120 | TFSVLACYNG | 10 |
7 | 123 | 129 | SGVYQCA | 7 |
8 | 153 | 162 | DYDCVSFCYM | 10 |
9 | 201 | 212 | TVNVLAWLYAAV | 12 |
10 | 244 | 253 | QDHVDILGPL | 10 |
11 * | 258 | 271 | GIAVLDMCASLKEL | 14 |
* 11 antigenic sites were predicted from the main protease. The underlined residues were also predicted as cytotoxic T-lymphocyte (CTL) epitope.